Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

1.0K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
1.0K
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

247
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
247
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

221
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
221
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Lung-Targeted γδ T Cell Nanovaccine Couples Pulmonary Immune Priming to Systemic Antitumor Immunity in Non-Small-Cell Lung Cancer.

ACS nano·2026
Same author

Interpretable machine learning for early prediction of acute kidney injury in critically ill patients with acute pancreatitis.

Digital health·2026
Same author

Dual-Functional Metallized Basalt Fiber with Exceptional Electromagnetic Interference Shielding and Joule Heating Capabilities under Simulated Lunar Temperature Conditions.

ACS applied materials & interfaces·2026
Same author

Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.

Genome medicine·2026
Same author

Ferroptosis in vascular injury of critically ill patients: implications of gut microbiota regulation.

Frontiers in cellular and infection microbiology·2026
Same author

The dialogue between breast cancer and microorganisms.

Frontiers in cellular and infection microbiology·2026

Related Experiment Video

Updated: Jan 10, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical Exposures.

Haider Inam1,2, Marta Tomaszkiewicz1,3, Joshua Reynolds1,3

  • 1Department of Biomedical Engineering, 211 Wartik Lab, The Pennsylvania State University, University Park, PA 16802, USA.

Biorxiv : the Preprint Server for Biology
|November 24, 2025
PubMed
Summary

Many cancer drug resistance variants lack characterization. This study introduces a method to classify these Variants of Uncertain Drug Resistance (VUDRs), potentially guiding treatment and reducing costs.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.0K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.2K

Related Experiment Videos

Last Updated: Jan 10, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.0K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.2K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Somatic mutations in oncogenes can cause anticancer drug resistance.
  • Many such variants are clinically uncharacterized, termed Variants of Uncertain Drug Resistance (VUDRs).
  • Lack of functional annotation for VUDRs hinders clinical management.

Purpose of the Study:

  • To develop a high-throughput platform for classifying drug resistance variants.
  • To assess the clinical implications of VUDRs for imatinib therapy.
  • To establish a generalizable framework for resistance variant classification.

Main Methods:

  • Deep mutational scanning was used to analyze 4922 imatinib resistance variants.
  • Quantitative concentration-response measurements were linked to human pharmacokinetic data.
  • 18 standards were used to validate performance across two orders of magnitude of drug sensitivity.

Main Results:

  • The platform demonstrated strong quantitative performance and clinical concordance.
  • Over 10% of analyzed clinical VUDRs conferred modest resistance, potentially manageable by dose escalation.
  • Ancestry-specific variants were identified, suggesting the potential for private VUDRs.

Conclusions:

  • A novel framework for high-throughput classification of drug resistance variants tied to human doses was established.
  • Findings suggest dose escalation with generic imatinib may overcome modest resistance, potentially reducing financial toxicity.
  • The study highlights the importance of characterizing VUDRs for personalized cancer therapy.